IN2014DN07812A - - Google Patents

Download PDF

Info

Publication number
IN2014DN07812A
IN2014DN07812A IN7812DEN2014A IN2014DN07812A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A IN 7812DEN2014 A IN7812DEN2014 A IN 7812DEN2014A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A
Authority
IN
India
Prior art keywords
reprogramming
methods
marks
epigenetic
mark readers
Prior art date
Application number
Other languages
English (en)
Inventor
Steven J M Jones
Oleksandr Yakovenko
Silvia Thoene
Pierre Yulmin Cheung
Jianghong An
Original Assignee
British Columbia Cancer Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency filed Critical British Columbia Cancer Agency
Publication of IN2014DN07812A publication Critical patent/IN2014DN07812A/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50Molecular design, e.g. of drugs
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60In silico combinatorial chemistry
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60In silico combinatorial chemistry
    • G16C20/64Screening of libraries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Library & Information Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN7812DEN2014 2012-02-27 2013-02-27 IN2014DN07812A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603650P 2012-02-27 2012-02-27
US201261637282P 2012-04-24 2012-04-24
PCT/CA2013/050145 WO2013127011A1 (en) 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer

Publications (1)

Publication Number Publication Date
IN2014DN07812A true IN2014DN07812A (enExample) 2015-05-15

Family

ID=49081499

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7812DEN2014 IN2014DN07812A (enExample) 2012-02-27 2013-02-27

Country Status (11)

Country Link
US (1) US9552457B2 (enExample)
EP (1) EP2819662B1 (enExample)
JP (1) JP6137703B2 (enExample)
KR (1) KR102149860B1 (enExample)
CN (1) CN104136020B (enExample)
AU (1) AU2013225592B2 (enExample)
BR (1) BR112014021201B1 (enExample)
CA (1) CA2865675C (enExample)
IN (1) IN2014DN07812A (enExample)
RU (1) RU2637441C2 (enExample)
WO (1) WO2013127011A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233198B2 (en) * 2013-03-15 2019-06-27 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
US20160214958A1 (en) * 2013-09-09 2016-07-28 Glionova Ab Compounds and use for treating cancer
EP3064205A1 (en) * 2015-03-06 2016-09-07 Glionova AB Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
EP3271485A4 (en) * 2015-03-18 2019-01-16 Memorial Sloan-Kettering Cancer Center METHOD FOR DIAGNOSIS AND TREATMENT OF FOLLICULAR LYMPHOMA
WO2017021229A1 (en) 2015-07-31 2017-02-09 Sanofi-Aventis Deutschland Gmbh Sensor, cartridge and drug delivery device
CA3079959A1 (en) * 2017-10-27 2018-10-26 Transfusion Health, Llc Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
WO2022081892A1 (en) * 2020-10-14 2022-04-21 The Regents Of The University Of California Systems for and methods of determining protein-protein interaction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE623404A (enExample) 1960-04-26
GB1120462A (en) 1964-07-06 1968-07-17 Manuf Prod Pharma 3-alkoxy-2h-fluoreno[1,9-ef]-1,4-diazepine 1-oxides and derivatives thereof
US3622580A (en) 1969-03-25 1971-11-23 Smith Kline French Lab Piperazino-acetylamino-9-fluorenones and-anthraquinones
LU85246A1 (fr) 1984-03-13 1985-10-14 R L Galephar Sa 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
IL141510A0 (en) * 1998-08-25 2002-03-10 Scripps Research Inst Method and systems for predicting protein function
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
CA2858520A1 (en) * 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
WO2009015283A2 (en) * 2007-07-24 2009-01-29 President And Fellows Of Harvard College Bhc80 - histone complexes and uses thereof
EP2331543A4 (en) 2008-09-26 2013-06-19 Agency Science Tech & Res 3-deazaneplanocin DERIVATIVES
WO2010045199A2 (en) 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
GB0822248D0 (en) * 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010094009A2 (en) 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
JP5886743B2 (ja) 2009-07-31 2016-03-16 アメリカ合衆国 抗血管新生性低分子および使用方法
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
CN103547152A (zh) 2011-02-23 2014-01-29 西奈山伊坎医学院 溴结构域蛋白的抑制剂作为基因表达的调节剂
WO2012123119A1 (en) 2011-03-17 2012-09-20 Cellzome Ag Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins
WO2013059944A1 (en) * 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof

Also Published As

Publication number Publication date
JP6137703B2 (ja) 2017-05-31
KR102149860B1 (ko) 2020-08-31
CN104136020A (zh) 2014-11-05
EP2819662A4 (en) 2016-03-23
AU2013225592B2 (en) 2017-11-09
WO2013127011A1 (en) 2013-09-06
AU2013225592A1 (en) 2014-10-09
US9552457B2 (en) 2017-01-24
BR112014021201A2 (pt) 2021-06-08
EP2819662B1 (en) 2019-04-10
EP2819662A1 (en) 2015-01-07
KR20140132382A (ko) 2014-11-17
RU2014138543A (ru) 2016-04-20
CN104136020B (zh) 2018-08-28
RU2637441C2 (ru) 2017-12-04
JP2015515448A (ja) 2015-05-28
CA2865675C (en) 2023-02-28
CA2865675A1 (en) 2013-09-06
BR112014021201B1 (pt) 2023-01-24
US20150154345A1 (en) 2015-06-04
AU2013225592A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
IN2014DN07812A (enExample)
PH12017501306A1 (en) Inhibitors of histone demethylases
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
GEP20166554B (en) Nitrogenated heterocyclic compound
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
MX362797B (es) Cateter de globo que puede ubicarse de manera mejorada.
PH12013500258B1 (en) Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds
MX381260B (es) Inhibidores heterociclicos de glutaminasa.
MX2015008403A (es) Cateter con marcas para facilitar alineacion.
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
PH12012501402A1 (en) Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
NZ627480A (en) Inhibitors of iap
BR112015029504A2 (pt) inibidores quinase
GB2514714A (en) Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue
MX2014011838A (es) Uso de neuregulina para tratar lesion de nervio periferico.
BR112014003096A2 (pt) uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk
EA201391304A1 (ru) 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке
IN2014DN09584A (enExample)
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
TN2015000020A1 (en) Molecular markers and methods for early sex determination in date palms
WO2014029888A3 (en) Branched or macrocyclic polyamines and uses thereof
MX2018010829A (es) Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial.
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
FR3000676B1 (fr) Composition de coloration d'oxydation comprenant un extrait huileux de fleurs de lotus, procede de coloration et dispositif approprie
PH12014502075A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours